The study compared five strategies: reducing the dosage of the iodinated dye alongside less tube voltage, weight-based dosage, using unenhanced CT instead of contrast CT if it’s safe, a combination of the first two solutions, and all three.
The research, which analyzed more than a million procedures from January 2015 to March 11, 2021, found that merging all three approaches issued the biggest reduction of up to 7.8 million milliliters, or 83 percent. Some hospitals and health systems have already rationed their dye usage.
In the U.S., more than 50 million scans are dependent on contrast dye annually to detect cancer and other diseases.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
